These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38797178)

  • 1. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Laxminarayan R; Impalli I; Rangarajan R; Cohn J; Ramjeet K; Trainor BW; Strathdee S; Sumpradit N; Berman D; Wertheim H; Outterson K; Srikantiah P; Theuretzbacher U
    Lancet; 2024 Jun; 403(10443):2534-2550. PubMed ID: 38797178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To Push or To Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority.
    Cama J; Leszczynski R; Tang PK; Khalid A; Lok V; Dowson CG; Ebata A
    ACS Infect Dis; 2021 Aug; 7(8):2029-2042. PubMed ID: 33606496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach.
    Mendelson M; Lewnard JA; Sharland M; Cook A; Pouwels KB; Alimi Y; Mpundu M; Wesangula E; Weese JS; Røttingen JA; Laxminarayan R
    Lancet; 2024 Jun; 403(10443):2551-2564. PubMed ID: 38797179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future.
    Ohashi T; Nagashima M; Kawai N; Ohmagari N; Tateda K
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1603-1614. PubMed ID: 36368311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings.
    Lucien MAB; Canarie MF; Kilgore PE; Jean-Denis G; Fénélon N; Pierre M; Cerpa M; Joseph GA; Maki G; Zervos MJ; Dely P; Boncy J; Sati H; Rio AD; Ramon-Pardo P
    Int J Infect Dis; 2021 Mar; 104():250-254. PubMed ID: 33434666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Available evidence and potential for vaccines for reduction in antibiotic prescriptions.
    Gabutti G
    Hum Vaccin Immunother; 2022 Dec; 18(7):2151291. PubMed ID: 36469620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interface between COVID-19 and bacterial healthcare-associated infections.
    O'Toole RF
    Clin Microbiol Infect; 2021 Dec; 27(12):1772-1776. PubMed ID: 34111586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovation in Antimicrobial Resistance: The CARB-X Perspective.
    Alm RA; Gallant K
    ACS Infect Dis; 2020 Jun; 6(6):1317-1322. PubMed ID: 32202756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
    Antimicrobial Resistance Collaborators
    Lancet; 2022 Feb; 399(10325):629-655. PubMed ID: 35065702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The COVID-19 Innovation System.
    Sampat BN; Shadlen KC
    Health Aff (Millwood); 2021 Mar; 40(3):400-409. PubMed ID: 33539184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to improve antibiotic access and a way forward for lower middle-income countries.
    Wasan H; Reeta KH; Gupta YK
    J Antimicrob Chemother; 2024 Jan; 79(1):1-10. PubMed ID: 38008421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of 4D's approach in curbing antimicrobial resistance among bacterial pathogens.
    Thakur L; Singh S; Singh R; Kumar A; Angrup A; Kumar N
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1401-1412. PubMed ID: 36098225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution.
    Piddock LJV; Paccaud JP; O'Brien S; Childs M; Malpani R; Balasegaram M
    Clin Infect Dis; 2022 May; 74(10):1866-1871. PubMed ID: 34618892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].
    Richter DC; Heininger A; Brenner T; Hochreiter M; Bernhard M; Briegel J; Dubler S; Grabein B; Hecker A; Krüger WA; Mayer K; Pletz MW; Störzinger D; Pinder N; Hoppe-Tichy T; Weiterer S; Zimmermann S; Brinkmann A; Weigand MA; Lichtenstern C
    Anaesthesist; 2017 Oct; 66(10):737-761. PubMed ID: 28980026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT.
    Harding C; Chadwick T; Homer T; Lecouturier J; Mossop H; Carnell S; King W; Abouhajar A; Vale L; Watson G; Forbes R; Currer S; Pickard R; Eardley I; Pearce I; Thiruchelvam N; Guerrero K; Walton K; Hussain Z; Lazarowicz H; Ali A
    Health Technol Assess; 2022 May; 26(23):1-172. PubMed ID: 35535708
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.